SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as investors debate the impact of potential institutional adoption and ongoing regulatory discussions, with the community split between bullish sentiment over long-term utility and skepticism regarding price manipulation. Conversations are dominated by traders monitoring the token's technical relationship with Bitcoin and speculation surrounding future banking partnerships.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crow with knife community is aggressively promoting the token as a multichain, deflationary meme coin, highlighting its presence on multiple networks and its organic, community-driven development. Enthusiasts are actively rallying around recent branding efforts, including a revamped website and ongoing ecosystem expansions, positioning the project as a standout player in the meme coin sector.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as investors speculate on potential integration with X payments and future utility, fueling a mix of bullish optimism and skepticism among the community. While some traders are focused on technical resistance levels and potential price breakouts, others remain cautious about historical volatility and the coin's long-term performance.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

ImmunityBio is currently trending as investors focus on the potential for massive addressable market expansion following an anticipated NCCN guideline update for Anktiva, which community members argue could fundamentally de-risk the company's financial profile. The stock is seeing significant attention as participants front-run a potential institutional upgrade cycle, with many highlighting its role within the broader SPDR S&P Biotech ETF sector recovery.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is gaining significant traction as a community-driven, permissionless brand, with holders actively coordinating to launch IRL products and services to expand their ecosystem. The community remains highly focused on building long-term value, using social media and grassroots initiatives to attract new participants despite broader market volatility.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP is generating intense community discussion as it navigates significant market volatility and ongoing institutional adoption following the launch of several spot ETFs. Traders are actively debating whether recent price fluctuations represent a temporary cooling-off period or a structural reset, with many focusing on the asset's long-term utility in cross-border payments versus its current speculative performance.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending as the community closely monitors for an imminent tenant announcement following the strategic hiring of a new CFO with significant data center financing experience. Investors are intensely debating the timeline for project development and the identity of the rumored hyperscaler partner, while actively tracking institutional accumulation as a signal for potential near-term price momentum.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan D. Green on March 5, 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is trending as investors weigh an expanded partnership with NVIDIA to leverage AI for autonomous mobility against broader concerns regarding stiff competition and recent quarterly performance. The community remains deeply divided, with many debating whether the current valuation and autonomous growth catalysts present a long-term buying opportunity or a signal to stay sidelined.

Silvaco Group, Inc. provides technology computer aided design software, electronic data automation software and semiconductor intellectual property. The TCAD, EDA and SIP solutions enable semiconductor and photonics companies to increase productivity, accelerate their product's time to market and reduce their development and manufacturing costs. Its services include SPICE Modeling Services, TCAD Modeling Services, Library Design Services and Library Characterization Services. The company was founded on November 18, 2009 and is headquartered in Santa Clara, CA.

Silvaco Group Inc.

Silvaco Group Inc. is trending as traders analyze the stock's recent volatility, including a significant price spike driven by massive volume and a subsequent cooling-off period. The community is actively debating the stock's potential for a momentum-based breakout, weighing its growth prospects in the semiconductor software sector against lingering concerns regarding financing, insider activity, and market-wide skepticism.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is currently a focal point for investors as it approaches its fourth-quarter and full-year earnings report, with the community actively debating the company's valuation floor and potential buyout prospects. Traders are monitoring high short interest and institutional accumulation, while discussion remains divided between those expecting positive guidance revisions and skeptics wary of recurring volatility around earnings releases.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Sable stated that it expects the first sale of hydrocarbons produced at its Santa Ynez Unit in April 2026 at an expected gross oil rate of 50,000 barrels per day.</li><li>The company said it anticipates a ramp-up in production, with full resumption at Platforms Harmony and Heritage this month and at Platform Hondo in June 2026.</li><li>Wright added that Sable’s production capacity could contribute to a 15% increase in California’s in-state oil production, replacing nearly 1.5 million barrels of foreign crude each month.</li></ul>Sable Offshore Corp. (SOC) shares soared more than 16% in Monday’s pre-market trade after the company announced that it has resumed the flow of oil produced at the Santa Ynez Unit (SYU) through Las Flores Canyon to Pentland Station in California.Sable stated that the resumption of oil flow between the two locations has been undertaken in accordance with an order issued by Energy Secretary Chris Wright. The order, issued on March 13, directed Sable to immediately prioritize and allocate pipeline transportation services for hydrocarbons between the two units.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/SOC">Sable Offshore</a> trended in the ‘extremely bullish’ territory with message volumes at ‘extremely high’ levels. SOC was among the top trending tickers on Stocktwits at the time of writing.<h2 class="st-heading-2">First Sale Expected In April</h2>Sable stated that it expects the first sale of hydrocarbons produced at its Santa Ynez Unit (SYU) in April 2026 at an expected gross oil rate of 50,000 barrels per day.The company said it anticipates a ramp-up in production, with full resumption at Platforms Harmony and Heritage this month and at Platform Hondo in June 2026.“Sable Offshore is putting California consumers first by increasing domestic supply of crude oil into the California market by approximately 17% and we look forward to continuing to execute as so ordered by the Defense Production Act executed on March 13, 2026,” said Sable CEO Jim Flores.<h2 class="st-heading-2">What Did Wright Order?</h2>On March 13, Wright ordered Sable to restore operations of the Santa Ynez Unit and Santa Ynez Pipeline System. He stated that California’s policies have left the region and U.S. military forces dependent on foreign oil.“Today’s order will strengthen America’s oil supply and restore a pipeline system vital to our national security and defense, ensuring that West Coast military installations have the reliable energy critical to military readiness,” he said.Wright added that Sable’s production capacity could contribute to a 15% increase in California’s in-state oil production, replacing nearly 1.5 million barrels of foreign crude each month.He stated that while California once supplied about 40% of U.S. oil production, 60% of its refined oil is now imported from overseas suppliers. Wright added that a “significant” share of these imports travels through the Strait of Hormuz, which Iran has currently blocked, presenting “serious national security threats,” according to the Energy Secretary.<a href="https://stocktwits.com/symbol/SOC">SOC stock</a> is up 87% year-to-date, but down 29% over the past 12 months. The SPDR S&amp;P Oil &amp; Gas Exploration &amp; Production ETF (XOP) is up nearly 37% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 24%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-nbis-stock-soaring-today/cZ32HbcRIfW">Why Is NBIS Stock Soaring Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

SOC Stock Rises Pre-Market After Energy Secretary Order Restarts Sable’s California Oil Pipeline

Energy Secretary Chris Wright issued the order to Sable on March 13, directing it to immediately prioritize and allocate pipeline transportation services for hydrocarbons between the two units.

Equity

<ul class="summary-bullets"><li>Roth Capital analyst Boobalan Pachaiyappan recommended buying shares of Capricor Therapeutics on Friday's selloff.</li><li>B. Riley, meanwhile, raised the firm's price target on CAPR to $63 from $50 and kept a ‘Buy’ rating on the shares.</li><li>The Food and Drug Administration has lifted the previously issued Complete Response Letter and resumed the review of the Biologics License Application for Deramiocel with a decision expected by August 22.</li></ul>Shares of Capricor Therapeutics (CAPR) fell 9% on Friday after the company reported a wider-than-expected Q4 loss but Wall Street analysts raised their price targets on the stock over hopes for an approval of the company’s lead candidate.On the company’s fourth-quarter (Q4) <a href="https://stocktwits.com/news-articles/markets/equity/capricor-reports-wider-quaterly-loss-than-expected-but-all-eyes-are-on-deramiocel/cZduNXsRIad">earnings</a> call, CEO Linda Marban <a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-best-week-month-ceo-rules-out-conditional-deramiocel-approval/cZdDdk4RIa1">rejected</a> the possibility that the Deramiocel therapy could receive only a conditional regulatory decision. The U.S. Food and Drug Administration is now expected to rule on Capricor's application for Deramiocel in the treatment of Duchenne Muscular Dystrophy by August 22, 2026, after reversing course on its previous rejection. DMD is a genetic disorder characterized by muscle degeneration.<h2 class="st-heading-2">Wall Street Take Aways</h2>Roth Capital analyst Boobalan Pachaiyappan recommended buying shares of Capricor Therapeutics on today's selloff. The 8% pullback is a "transient, healthy and short-lived market correction" following the rally post FDA acceptance of Capricor's application of Deramiocel for the treatment of Duchenne muscular dystrophy, the analyst told investors in a research note. Roth would be buying today's "dislocation" and expects the share price to move towards its price target of $41. The firm has a ‘Buy’ rating on Capricor.B. Riley, meanwhile, raised the firm's price target on CAPR to $63 from $50 and kept a ‘Buy’ rating on the shares. The analyst said that its confidence has increased in a potential smooth approval path for Deramiocel ahead of the August 22 decision date, with shares expected to build into the decision as investors digest additional dataset, the analyst told investors in a research note.Piper Sandler raised the firm's price target on CAPR to $58 from $45 and kept an ‘Overweight’ rating on the shares. The firm noted Capricor ended 2025 with cash of $318 million to fund operations through 2027. The FDA has lifted the previously issued Complete Response Letter and resumed the review of the Biologics License Application for Deramiocel with a decision expected by August 22. Optimistically, the label could include the broad Duchenne muscular dystrophy population, not just DMD cardiomyopathy, Piper argues.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock remained within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained 138% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-will-delay-release-of-cybercab-until-late-2026-owing-to-safety-issues-fund-manager-predicts/cZdDVgaRIO9">Tesla Will Delay The Release Of Cybercab Until Late-2026 Owing To Safety Issues, Fund Manager Predicts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval

On the company’s fourth-quarter (Q4) earnings call on Thursday, CEO Linda Marban rejected the possibility that the Deramiocel therapy could receive only a conditional approval.

Eastman Kodak’s shares rallied nearly 12% in extended hours of trading on Thursday after it reported strong growth in its fourth-quarter revenue.&nbsp;Kodak reported consolidated revenues of $290 million in the fourth quarter of 2025, compared with $266 million in the year-ago period, an increase of $24 million or 9%. The rise in revenue was driven by strong performance in Advanced Materials &amp; Chemicals (AM&amp;C) and Print segments.&nbsp;“Kodak ended 2025 with a strong fourth quarter, which has created a foundation for growth in 2026,” said Jim Continenza, Kodak’s Executive Chairman and CEO. “We continue to execute the long-term plan we began in 2019, which focuses on de-levering the company while continuing to invest in our infrastructure and new product innovation”.&nbsp;Kodak ended the year with a cash balance of $337 million, an increase of $136 million from December 31, 2024. The increase was primarily due to the net impact of the Kodak Retirement Income Plan (KRIP) termination and reversion of assets to the company of $153 million.The company reported GAAP net loss of $108 million in Q4 2025, compared with net income of $26 million for Q4 2024. The decline in net income was primarily due to the non-recurring impact of the Kodak Retirement Income Plan ("KRIP") termination and excise tax paid on the reversion of assets to the company.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around KODK stock trended in ‘bullish’ territory amid ‘extremely high’ message volume.&nbsp;One user on Stocktwits called the share rise ‘better than expected’.<stembedurl>https://stocktwits.com/PharmGal/message/647406000</stembedurl>A bullish user said they are optimistic for Kodak in 2026.&nbsp;<stembedurl>https://stocktwits.com/NikkyBenz13/message/647405165</stembedurl>Another bullish user opined that continued growth in Kodak’s Advanced Materials &amp; Chemicals is especially encouraging and could open doors to new markets.&nbsp;<stembedurl>https://stocktwits.com/Judykay/message/647399877</stembedurl>Shares in the company are down 9.4% so far in 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, the Eastman Kodak Company logo is seen displayed on a smartphone screen.

Eastman Kodak Stock Rallies After-Hours As Q4 Revenue Jumps On Strong Segment Performance

Kodak reported consolidated revenues of $290 million in the fourth quarter of 2025, compared with $266 million in the year-ago period, an increase of $24 million or 9%.

<ul><li>The company reported no revenue for the period, and ended 2025 with cash, cash equivalents, and marketable securities of about $318.1 million.</li><li>Capricor is now awaiting the U.S. Food and Drug Administration’s decision on the application for Deramiocel by August 22.</li><li>The FDA reversed course on its previous rejection for Deramiocel earlier this week.</li></ul>&nbsp;Shares of Capricor Therapeutics (CAPR) slid down about 2% after-hours on Thursday, after the company reported wider-than-expected quarterly loss, partially offset by optimism for the company’s pipeline.For the fourth quarter, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/340/capricor-therapeutics-reports-fourth-quarter-and-full-year">reported</a> a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024, and more than a Wall Street estimate of a loss of $0.54.The company reported no revenue for the period, and ended 2025 with cash, cash equivalents, and marketable securities of about $318.1 million. The company now believes this to be sufficient to cover anticipated expenses and capital requirements though 2027.<h2 class="st-heading-2">Optimism For Deramiocel Application</h2>The company is now awaiting the U.S. Food and Drug Administration’s decision on the application for Deramiocel by August 22. If approved, the company said that its San Diego GMP manufacturing facility will support a potential commercial launch.“Capricor enters 2026 with important regulatory and clinical momentum as we work toward potential approval of Deramiocel for the treatment of Duchenne muscular dystrophy (DMD),” said Linda Marbán, CEO of Capricor.The FDA is now expected to rule on Capricor's application for Deramiocel in the treatment of Duchenne Muscular Dystrophy by August 22, 2026, after reversing course on its previous rejection. DMD is a genetic disorder characterized by muscle degeneration.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock stayed within ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained about 156% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fly-stock-rallies-on-wall-street-spiking-optimism-after-succesful-alpha-launch/cZdujXtRIaP">FLY Stock Rallies On Wall Street’s Spiking Optimism After Successful Alpha Launch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Capricor Reports Wider Quarterly Loss Than Expected But All Eyes Are On Muscle Disease Therapy

For the fourth quarter, the company reported a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024.

<ul class="summary-bullets"><li>The company swung to profit in Q4 and reported earnings per share of $0.05 versus year-ago loss per share of $0.22.</li><li>Adjusted operating expenses for the fourth quarter of 2025 were $6.5 million compared to $11.9 million for the fourth quarter of 2024.</li><li>On Stocktwits, retail sentiment around DMRC&nbsp;stock trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;</li></ul>DigiMarc (DMRC) shares rallied 7% during extended hours of trading after it reported a&nbsp;higher-than-expected&nbsp;fourth-quarter (Q4) revenue on Wednesday.&nbsp;DMRC’s total revenue for Q4 2025 was $8.9 million compared to $8.7 million for the fourth quarter of 2024. Analysts on average expected $8.2 million in revenue, as per data from&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://fiscal.ai">Fiscal.ai</a>.&nbsp;<h2 class="st-heading-2">Q4 Snapshot</h2>DigiMarc’s subscription revenue for Q4 2025 came at $5.3 million compared to $5.0 million for the fourth quarter of 2024. The increase reflects $1.4 million of patent license fees earned during the quarter and higher subscription revenue from new and existing commercial contracts, partially offset by a $1.4 million decrease relating to the expiration of two previously disclosed commercial contracts in 2025,&nbsp;the company said.The company's adjusted net income for Q4 2025 was $1.0 million or $0.05 per diluted share compared to adjusted net loss of $4.6 million or $0.22 per diluted share for the fourth quarter of 2024.“Digimarc is capitalizing on the convergence of key trends driving increased demand for our solutions, positioning ourselves to benefit from - not be the casualty of - the relentless advance of AI," said Riley McCormack, Digimarc CEO. "In Q4 2025, we achieved both positive non-GAAP net income and positive free cash flow. Looking ahead to 2026, we expect to generate significant ARR growth."<h2 class="st-heading-2">Expenses Come Down</h2>Operating expenses for the quarter were $10.0 million, compared to $14.4 million for Q4 2024.&nbsp;The decrease was led by lower cash compensation costs of $4.4 million, largely due to lower headcount, and lower professional services costs of $0.6 million, partially offset by higher stock compensation costs of $0.7 million.&nbsp;Adjusted operating expenses for the quarter were $6.5 million compared to $11.9 million for Q4 2024.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around DMRC&nbsp;stock trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company have fallen 9.4% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Stocktwits, retail sentiment around DMRC stock trended in ‘extremely bullish’ territory amid ‘high’ message volume. 

DigiMarc Stock Rallies After Hours On Q4 Revenue Beat

DMRC’s total revenue for the fourth quarter of 2025 was $8.9 million compared to $8.7 million for the fourth quarter of 2024.

<ul class="summary-bullets"><li>The company said it expects Bumble App Revenue of $171 million to $174 million for Q126.</li><li>In Q4, total revenue decreased 14.3% to $224.2 million, compared to $261.6 million from the year-ago quarter.</li></ul>Shares of Bumble rallied nearly 25% during Wednesday’s extended hours of trading as upbeat outlook for first-quarter revenue cushioned worries from weakness in fourth-quarter earnings.&nbsp;&nbsp;The company said it expects total&nbsp;revenue&nbsp;for Q1 2026 to be in the range of $209 million to $213 million, which includes Bumble App Revenue of $171 million to $174 million. Analysts on average&nbsp;estimate revenue of $210 million.&nbsp;BMBL expects adjusted core profit in the range of $76 million to $80 million for the quarter.<h2 class="st-heading-2">Weak Q4</h2>Total Revenue decreased 14.3% to $224.2 million, compared to $261.6 million from the year-ago quarter. Bumble App revenue also fell 14.8% to $181.0 million, compared to $212.4 million.Bumble’s Total Paying Users slumped 20.5% to 3.3 million, compared to 4.2 million.The company said&nbsp;its fourth quarter net loss was $611.1 million, compared to net earnings of $9.3 million from the year-ago quarter.&nbsp;<h2 class="st-heading-2">FY 2025</h2>In FY2025, Bumble’s total revenue decreased 9.9% to $965.7 million, compared to $1.07 billion. Total Paying Users decreased 11.5% to 3.7 million, compared to 4.1 million.&nbsp;“In 2025, we made the deliberate choice to return Bumble to its women-first foundation, raising the bar on trust and authenticity while addressing pain points our members experience with online dating,” said Whitney Wolfe Herd, Founder &amp; CEO of Bumble Inc.“With the heavy lift of our quality reset behind us, we are accelerating product innovation and prioritizing member experience enhancements. We are building from a stronger base and positioning Bumble for its next chapter of product-led growth,” Herd said.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around BMBL trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares in BMBL have fallen 2.4% year-to-date.&nbsp;

The exterior of Bumble Headquarters on July 15, 2024 in Austin, Texas. 

Bumble Stock Is Rallying Today After Hours – What Is Causing The Bull Run?

The company said it expects total revenue for Q1 2026 to be in the range of $209 million to $213 million. Analysts on average estimate revenue of $210 million. 

<ul class="summary-bullets"><li>The only drug-related adverse events observed are typically anticipated with gene therapy administration, the company noted.</li><li>It added that a proactive, short-course immune modulation regimen in combination with a differentiated construct and industry-leading product purity levels may contribute to a favorable safety profile for RGX-202.&nbsp;</li><li>Sarepta Therapeutics’s FDA-approved DMD gene therapy Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths.</li></ul>REGENXBIO Inc. (RGNX) on Wednesday announced positive interim data from the company’s early-to-mid stage trial of its gene therapy for Duchenne muscular dystrophy.The investigational gene therapy RGX-202 demonstrated evidence of positively changing disease trajectory for the disease in a few patients enrolled in the trial. It further exhibited a favorable safety profile with no serious adverse events and no evidence of liver injury, the company said.The only drug-related adverse events observed are typically anticipated with gene therapy administration, the company noted, while adding that a proactive, short-course immune modulation regimen in combination with a differentiated construct and industry-leading product purity levels may contribute to a favorable safety profile for RGX-202.Sarepta Therapeutics’s (SRPT) FDA-approved DMD gene therapy, Elevidys, came under scrutiny last year over concerns of acute liver failure and associated patient deaths. Duchenne muscular dystrophy (DMD) is a severe, progressive genetic muscle disease affecting mostly boys.<h2 class="st-heading-2">Application Timeline</h2>REGENXBIO now expects to share topline data from the trial in early second quarter and request a meeting with the FDA in mid-2026, ahead of filing an application seeking approval for the gene therapy.In the meantime, the company will continue to enroll participants for its confirmatory trial, which is expected to have about 30 participants. The company said on Wednesday that it expects to have the majority of the trial enrolled at the time of the application submission.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around RGNX stock fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘extremely low’ levels.<a href="https://stocktwits.com/symbol/RGNX">RGNX stock</a> has gained nearly 54% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/joby-aviation-makes-first-steps-towards-faa-certification-of-aircraft/cZdrOkARIBb">Joby Aviation Makes First Steps Towards FAA Certification Of Aircraft</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Regenxbio Says Its Gene Therapy For Muscle Disorder Showed No Evidence Of Liver Injury In Study 

The investigational gene therapy RGX-202 exhibited a favorable safety profile with no serious adverse events and no evidence of liver injury, the company said. 

<ul class="summary-bullets"><li>The onshore pipelines of SOC have been shut down for a decade since the 2015 Refugio Beach oil spill.</li><li>The efforts come at a time when the U.S.-Israel war with Iran has disrupted global supply of oil and other key energy products.</li><li>Sable in December had said that it received an emergency special permit from PHMSA for Santa Ynez Pipeline System Segments.</li></ul>U.S. President Donald Trump is reportedly set to summon authorities under the Defense Production Act to preempt state laws and ease permitting for Sable Offshore Corp. (SOC)&nbsp; to restart significant production from a cluster of offshore platforms in California.According to a Bloomberg News report, a White House official said that any policy announcement would come directly from the president.&nbsp;The efforts come at a time when the U.S.-Israel war with Iran has disrupted global supply of oil and other key energy products due to the blockade of Strait of Hormuz by Iran.&nbsp;The onshore pipelines have been shut down for a decade since the 2015 Refugio Beach oil spill, when a corroded segment of one pipeline ruptured and released hundreds of thousands of gallons of oil near Santa Barbara.Shares of&nbsp;SOC jumped 18% at the time of writing.&nbsp;&nbsp;<h2 class="st-heading-2">SOC’s Feud</h2>California Attorney General Rob Bonta earlier in the month filed a lawsuit against the Trump Administration, challenging the Pipeline and Hazardous Materials Safety Administration’s (PHMSA) orders that “illegally assert” exclusive jurisdiction over two California onshore oil pipelines of Sable offshore which are known as the Las Flores Pipelines or lines CA-324 and CA-325, and allow them to restart operations.Sable in December had said that it received a receipt of an emergency special permit from PHMSA for Santa Ynez Pipeline System Segments.<h2 class="st-heading-2">IEA Announcement</h2>Earlier in the day, the International Energy Agency announced that all its 32 member countries had unanimously agreed to release 400 million barrels of oil from their emergency reserves to help address disruptions in oil markets caused by the war in the Middle East.Retail sentiment around SOC trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in SOC have jumped 59.4% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

A crane ship helps other vessels searching for oil and natural gas near the oil platform offshore the Red Sea in Ras Behar region, Egypt.

Sable Offshore To Reportedly Get Trump Support Via Emergency Law To Restart Production

A White House official said that any policy announcement would come directly from the president, as per a Bloomberg News report. 

<ul class="summary-bullets"><li>Domo also reported EPS of $0.03, while the Street expected the company to post a loss of $0.03 per share.&nbsp;</li><li>Despite the strong results, Lake Street lowered its price target on Domo to $7 from $13 and kept a ‘Hold’ rating on the shares, as per TheFly.&nbsp;</li><li>Cantor Fitzgerald cut the price target on the company to $8 from $13 and maintained an ‘Overweight’ rating on the shares, citing lower overall software multiples.</li></ul>Domo Inc. (DOMO), a cloud software company that leverages artificial intelligence to provide real-time business data to improve executive decision-making, posted fourth-quarter (Q4) results on Tuesday that beat analysts’ expectations.Despite the strong results, Wall Street analysts slashed price targets on the company. Lake Street lowered its price target on Domo to $7 from $13 and kept a ‘Hold’ rating on the shares, as per TheFly.DA Davidson and Cantor Fitzgerald also lowered their price targets on the Utah-based company.<h2 class="st-heading-2">Street Rationale</h2>Lake Street analyst Eric Martinuzzi said the lowered price target reflected a fair takeout price for the growth-challenged SaaS business after the company said in its earnings release that it expects revenue to be flat in FY27 with modest growth in its earnings per share.DA Davidson analyst Lucky Schreiner lowered the price target on Domo to $6 from $10 and kept a ‘Neutral’ rating on the shares. While the firm noted Domo’s strong Q4 results, it said that it is waiting to see more upside to revenue growth prospects before becoming more constructive.Cantor Fitzgerald cut the price target on the company to $8 from $13 and maintained an ‘Overweight’ rating on the shares, citing lower overall software multiples.Based on data from Koyfin, Wall Street has a 12-month average target of $9.58 on Domo shares, representing an upside potential of about 90% compared to the current price levels of $5.04.<h2 class="st-heading-2">Domo Q4 Snapshot</h2>The SaaS company posted a marginal 1% growth in Q4 revenue, coming in at $79.6 million, higher than consensus estimates of $79.03 million. Domo also reported EPS of $0.03, while the Street expected the company to post a loss of $0.03 per share.However, the company refrained from providing specific forward-looking guidance, citing ongoing evaluation of strategic alternatives. The company’s CFO, Tod Crane, however clarified that Domo expects GAAP revenue to remain relatively flat for fiscal year 2027, and modest improvement in non-GAAP EPS and positive adjusted free cash flow.<h2 class="st-heading-2">Retail Sentiment</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/DOMO">DOMO shares</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volumes climbed to ‘extremely high’ levels.Shares of DOMO climbed after the results, and continued to increase on Wednesday. In the past year, DOMO stock has declined more than 37%.Meanwhile, <a href="https://stocktwits.com/symbol/IWM">iShares Russell 2000 ETF</a> (IWM) has climbed by over 25% in the past year, while the <a href="https://stocktwits.com/symbol/VTI">Vanguard Total Stock Market Index Fund ETF</a> (VTI) has gained more than 21%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a US flag is displayed on a smartphone and stock market prices in the background. (Photo Illustration by Romain Doucelin/SOPA Images/LightRocket via Getty Images)

Domo Posted A Double Beat On Q4 Results — So Why Is The Street Slashing Targets?

The cloud software company posted Q4 results on Tuesday, with revenue coming in at $79.6 million, higher than consensus estimates of $79.03 million.

<ul class="summary-bullets"><li>On Stocktwits, retail sentiment around ALDX stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.</li><li>Aldeyra resubmitted its application seeking approval for the drug in July after previous rejections.&nbsp;</li><li>While the agency was initially expected to rule on the application by December, it later extended it until March 16.</li></ul>Shares of Aldeyra Therapeutics (ALDX) garnered retail attention on Stocktwits on Tuesday as the company approaches the date for potential approval of its dry eye treatment Reproxalap.The U.S. Food and Drug Administration (FDA) is slated to rule on the company’s application seeking approval for Reproxalap by March 16. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ALDX stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.Users are sharply divided between hopes for approval following a draft label and a recent procedural extension, and concerns over prior rejections.A Stocktwits user expressed optimism for an imminent approval, saying that the FDA has never rejected a drug so many times.<stembedurl>https://www.stocktwits.com/Dragan7/message/647163937</stembedurl>Another expressed hopes for more information as early as Thursday.<stembedurl>https://www.stocktwits.com/UpAndDownUpAndDown/message/647145449</stembedurl><a href="https://stocktwits.com/symbol/ALDX">ALDX stock</a> has dropped 24% over the past 12 months.<h2 class="st-heading-2">Approval Updates</h2>Aldeyra resubmitted its application seeking approval for Reproxalap in July after <a href="https://stocktwits.com/news-articles/markets/equity/aldeyra-therapeutics-stock-slumps-after-fda-letter/chf7PxrRbe1">previous rejections</a>. &nbsp;While the agency was initially expected to rule on the application by December, it later extended it until March 16 to review the additional submissions made by the company as proof of efficacy of its therapy. The company then said that the FDA made no requests or flagged any specific issues with its application review in a meeting in December.Aldeyra first submitted an application to the FDA for Reproxalap in November 2022, but the agency asked for more trials. The company subsequently resubmitted its application in October 2024 but it was rejected in April with the FDA saying the company’s trials failed to demonstrate its efficacy.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/qure-stock-edges-up-after-hours-as-analyst-flags-reduced-regulatory-uncertainty-after-prasad-fda-exit/cZdY5SrRI7s">QURE Stock Edges Up After Hours As Analyst Flags Reduced Regulatory Uncertainty Following Prasad’s FDA Exit</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aldeyra Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ALDX Stock Garners Retail Interest: Investors Debate Dry Eye Treatment Approval Amid Long Wait

The U.S. Food and Drug Administration is slated to rule on the company’s application seeking approval for Reproxalap by March 16.  

iShares Trust - iShares Russell 2000 ETF

Up 5%

Down 5%

Show me the results

Which direction is the next 5% move for the S&amp;P 500?

Stocktwits

Which direction is the next 5% move for the S&P 500?

Stocktwits Polls

iShares Russell 2000 ETF

Geopolitical tensions surrounding Iran and the Strait of Hormuz are driving oil prices above $100, fueling inflation fears and causing broad market anxiety.

Latest economic data reveals a significant slowdown in US Q4 GDP growth to 0.7% and a higher core PCE inflation reading, putting renewed pressure on Fed rate decisions.

Traders are keenly watching critical price levels for the small-cap index, with $250 acting as strong resistance and $245 being tested as a key support after breaking new year-to-date lows.

CBOE's proposal for near 24x5 US equities trading in Dec 2026, alongside discussions of 0DTE income ETFs, signals evolving market structure and trading product interest.

IWM
iShares Russell 2000 ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IWM News

IWMiShares Russell 2000 ETF